Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-25
2011-01-25
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252030, C544S238000
Reexamination Certificate
active
07875615
ABSTRACT:
The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
REFERENCES:
patent: 2503059 (1950-04-01), Miescher et al.
patent: 2599000 (1952-01-01), Kerwin et al.
patent: 3381009 (1968-04-01), Palazzo et al.
patent: 3511836 (1970-05-01), Hess et al.
patent: 3527761 (1970-09-01), Archibald et al.
patent: 3997666 (1976-12-01), Witte et al.
patent: 4026894 (1977-05-01), Winn et al.
patent: 4188390 (1980-02-01), Campbell et al.
patent: 4252721 (1981-02-01), Silvestrini et al.
patent: 4315007 (1982-02-01), Manoury et al.
patent: 4703063 (1987-10-01), Imai et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5693652 (1997-12-01), Takase et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5861396 (1999-01-01), Niewohner et al.
patent: 5945117 (1999-08-01), El-Rashidy et al.
patent: 2004/0067945 (2004-04-01), Niewohner et al.
patent: 0995750 (1999-10-01), None
patent: 0995751 (1999-10-01), None
patent: 1092718 (2000-10-01), None
patent: 1092719 (2000-10-01), None
patent: 1097719 (2000-11-01), None
patent: 1293503 (2001-05-01), None
patent: WO 9307149 (1993-04-01), None
patent: WO 9312095 (1993-06-01), None
patent: WO 9400453 (1994-01-01), None
patent: WO 9519978 (1995-07-01), None
patent: WO 9830560 (1998-07-01), None
patent: WO 9849166 (1998-11-01), None
patent: WO 9902159 (1999-01-01), None
patent: WO 9930697 (1999-06-01), None
patent: WO 9954333 (1999-10-01), None
patent: WO 0002550 (2000-01-01), None
patent: WO 0024745 (2000-05-01), None
patent: WO 0028993 (2000-05-01), None
patent: WO 0127112 (2001-04-01), None
patent: WO 0127113 (2001-04-01), None
patent: WO 0158880 (2001-08-01), None
patent: WO 0187855 (2001-11-01), None
patent: WO 03053437 (2003-07-01), None
“Tautomer.” Retrieved online via the Internet, Feb. 11, 2008, URL: http://en.wikipedia.org.giki/Tautomer.
Kakefuda et al., [5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human Vasopressin V1A Receptor, J. Med. Chem, 45 (2002) 2589-2598].
Akerlund, Mats,Annals New York Academy Of Sciences, “Vascularization of Human Endometrium”, pp. 47-55.
Arletti, et al.,Peptides, “Influence of Oxytocin on Feeding Behavior in the Rat”, vol. 10, pp. 89-93, (1989).
Berman, et al.,Urology, “Female Sexual Dysfunction: Incidence, Pathophysiology, Evauation, and Treatment Options”, vol. 54, pp. 385-391, (1999).
Berman, et al,International Journal of Impotence Research, “Definition and classification of female sexual disorders”, vol. 10 (S-2), pp. S-104-S106, (1998).
Clemence, et al.,European Journal of Med. Chem. “Synthesis and Analgesic Activity in the 1,2,4-Triazole Series”, vol. 20(3); pp. 257-266, (1985).
Gimpl, et al,Physiological Reviews, “The Oxytocin Recptor System: Structure, Function, and Regulation”, vol. 81(2), pp. 629-683, (2001).
Melman, et al,The Journal of Urology, “The Epidemiology and Pathophysiology of Erectile Dysfunction”, vol. 161 (1), pp. 5-11, (1999).
Nicholson, et al.,Advanced Exp. Med. &Biology, “Oxytocin and Prostatic Function”, pp. 529-538 (1995).
Rotella, et al.,Journal of Med. Chemistry, “N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction”, vol. 43, pp. 1257-1263, (2000).
Truitt, et al.,Science, “Identification of a Potential Ejaculation generator in the Spinal Cord”, vol. 297, pp. 1566-1569, (2002).
Brown Alan Daniel
Ellis David
Smith Christopher Ronald
Anderson Rebecca L
Kispert Jennifer A.
Pfizer Inc
Shterengarts Samantha L
Wichtowski John A.
LandOfFree
Substituted triazole derivatives as oxytocin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted triazole derivatives as oxytocin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted triazole derivatives as oxytocin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696780